Articles tagged with Neurodegenerative Diseases
Researchers at University of Virginia Health System discovered that an immune molecule called STING drives the formation of harmful plaques and protein tangles associated with Alzheimer's. Blocking STING protected lab mice from mental decline, suggesting a promising treatment target for neurodegenerative diseases.
Researchers at UT Health San Antonio discovered associations between blood lipid levels and Alzheimer's disease risk. Higher small dense cholesterol particles increased risk, while ApoB48 levels were associated with lower risk.
Researchers from Florida Atlantic University have discovered a potentially safer treatment for multiple disorders linked to altered dopamine signaling by blocking the kappa opioid receptor. The study found that this approach can correct behavioral deficits and normalize dopamine availability.
A team of researchers from CRCHUM has identified a set of biomarkers in blood samples that could help diagnose Parkinson's disease. The study found that immune cells in the blood were activated and overexpressed genes associated with stress responses in patients with Parkinson's, forming a unique genetic signature.
A new study from the University of Georgia finds that rural counties in Georgia lack access to PET scan facilities and lecanemab infusion centers, making it difficult for patients to receive diagnosis and treatment. The researchers highlight the need for increased resources and support for rural patients with Alzheimer's disease.
Researchers used a new fMRI analysis method to measure cerebrovascular reactivity in 53 adults aged 51-83. They found an unexpected improvement in brain health in postmenopausal female participants, primarily in areas related to movement and memory.
The ATN dataset is a multi-cohort study that includes harmonised clinical and biomarker data from over 350 participants across ten European research cohorts. This dataset provides valuable insights into shared disease mechanisms among Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Bodies.
Researchers have discovered a new drug that protects the blood-brain barrier, preventing neurodegeneration and cognitive impairment in Alzheimer's disease. The drug targets an enzyme that damages the BBB, which is also affected in traumatic brain injury and aging.
Researchers at UCLA Health identified a candidate small molecule, DDL-357, that increases concentrations of secreted clusterin, reducing toxic protein phospho-tau and improving mitochondrial function. The drug also improved memory in treated mice in maze-based cognitive tests.
Scientists at MIT have identified new potential targets for treating Alzheimer's disease, including a pathway involved in DNA damage repair. The study suggests that a combination of treatments targeting different cellular pathways may be more effective in blocking disease progression.
A protein complex has been identified that repairs abnormal DNA responsible for neurodegenerative disease Huntington's. This discovery could lead to the development of a therapeutic target to delay or prevent disease onset.
Research highlights potential link between microplastics in ultra-processed foods and brain health, with possible connections to depression and dementia. The studies propose a novel hypothesis connecting ultra-processed food consumption, microplastic exposure, and mental health outcomes.
Davis Joseph's groundbreaking discovery identifies a common master switch that can cure multiple brain-related diseases with a single method. The unified theory establishes that regulating axon-based 4E-BP2 protein deamidation can control disease progression.
The USC Parris Longevity Accelerator aims to develop early interventions for age-related diseases, including osteoarthritis and cardiovascular disease, through AI-driven diagnostic tools and targeted therapeutics. The initiative could lead to therapies that preserve mobility and restore strength in older adults.
Researchers at UC San Francisco have identified potential protein markers for frontotemporal dementia (FTD), a form of dementia affecting middle age. The study found changes in RNA regulation and brain connections that could lead to early diagnosis and targeted treatments.
Researchers found that astrocytes transmit signals, revealing new ways the brain processes information. The study provides direct evidence for the real-time action of astrocytes in live brains of fruit flies, suggesting their role in mediating neurophysiology and behavior.
A new technique using focused sound waves and microbubbles has shown great promise in treating debilitating brain lesions called cerebral cavernous malformations. The approach has halted the growth of lesions almost entirely, offering a potential paradigm shift in treatment.
Researchers at Mass General Brigham have pinpointed a 'sweet spot' for focused ultrasound treatment to provide significant relief from essential tremor. The study identified a specific subregion of the brain's thalamus that can result in optimal and long-lasting tremor improvements while reducing side effects. With this breakthrough, p...
Cognivue launches CARM, a novel metric predicting amyloid presence and enabling early Alzheimer's detection. The CARM score combines age with cognitive subtests to generate a four-point risk score indicating the likelihood of amyloid presence in the brain.
Scientists have developed a sugar-coated nanotherapy that effectively traps misfolded proteins, neutralizing their toxic effects on neurons. The treatment significantly boosts the survival of lab-grown human neurons under stress from disease-causing proteins.
Zhaoqi Yan, a scientist at Gladstone Institutes, has been awarded the 2025 Warren Alpert Distinguished Scholar fellowship to investigate the molecular mechanisms behind blood-brain barrier dysfunction. His research aims to develop new therapeutic strategies for neurological diseases, including Alzheimer's.
A new University of Georgia study found that Black Americans with high blood pressure and diabetes in midlife had significantly higher levels of a dementia-related biomarker over an 11-year period. Early intervention for these chronic health conditions could protect brain health and reduce neurodegenerative diseases later in life.
A team of researchers has discovered a small molecule that can selectively block cell death, which could lead to new treatments for neurodegenerative conditions. By targeting the killer protein BAX, the molecule can prevent excessive cell death in neurons, potentially slowing or halting disease progression.
A new study reveals how a promising Parkinson's drug works by inhibiting the enzyme USP30, which prevents damaged mitochondria from being degraded. This breakthrough could lead to targeted therapies for Parkinson's disease and chronic kidney disease.
A study published in JAMA Neurology found no evidence supporting a diagnosis of the New Brunswick neurological syndrome of unknown cause, highlighting the need for independent clinical evaluations. The data revealed presence of several neurodegenerative and non-neurodegenerative conditions instead
Alzheimer's disease and other dementias are rising rapidly in China due to population growth and high-risk factors like high blood sugar, smoking, and obesity. The study projects continued rise unless effective interventions are implemented.
A new study from Washington University School of Medicine found that 81% of participants would choose to know their theoretical risk, but only 60% opted for real results. The research highlights the importance of considering ethical concerns and ensuring participants truly want their research results.
The MED13L Foundation has launched a three-year natural history study at Boston Children's Hospital to better understand MED13L Syndrome and inform future clinical trials. The study will collect data from 30 individuals with the condition over three years, providing valuable insights into disease progression and development.
Researchers discovered two proteins, GSK3ß and ERK1, that regulate the movement of a toxic huntingtin protein in neurons. Inhibiting GSK3ß led to reduced axonal blockages and neuronal cell death, while inhibiting ERK1 had the opposite effect, increasing transport problems and cell death.
A team of researchers has developed a predictive model that uses genetic mutations to forecast the age of onset for familial Alzheimer's disease. The model suggests specific correlations between gene mutations and disease progression, enabling clinicians to tailor treatment strategies and improve early diagnosis.
Researchers at KAIST have identified a key mechanism behind neuroinflammatory responses in Parkinson's disease, which is regulated by an RNA editing enzyme called ADAR1. This discovery suggests that targeting this enzyme could serve as a novel therapeutic strategy for treating the disease.
Researchers identified key tasks in a speech assessment battery to detect primary progressive aphasia, a rare neurodegenerative disease. Early detection can lead to slower disease progression and improved communication skills.
A protein link between brain diseases and leaky blood vessels reveals that endothelial cell dysfunction plays a crucial role in the progression of neurodegenerative diseases. The study found that reduced TDP-43 levels lead to gaps in blood vessel walls, allowing toxic molecules to enter the brain.
Researchers at UCSF found clinically significant improvements in mood, cognition, and motor function after psilocybin therapy for patients with mild to moderate Parkinson's disease. The study suggests that psilocybin could provide relief from multiple symptoms of the disease by reducing inflammation and promoting neuroplasticity.
Researchers develop a simplified model of tau protein that forms disease-like fibrils, shedding light on the fundamental interactions underlying neurodegenerative diseases. The 'mini prion' can recreate the critical hallmarks of tauopathies, such as Alzheimer's disease.
A new study led by University College London researchers found that people with Alzheimer's disease scored slightly higher on a measure of empathy than peers with mild cognitive impairment. Despite this, emotional reactivity to negative emotions was heightened among those with Alzheimer's disease, contributing to difficulties regulatin...
Researchers found that ATP regulates protein condensation and cytoplasm viscosity, preventing harmful protein aggregates. Boosting ATP production decreases viscosity, dispersing existing and preventing future protein aggregations.
A rodent study found hnRNP A1 regulates myelin production and maintains its integrity, suggesting an impact on neurodegenerative diseases like schizophrenia. The findings provide new insights into the disease's molecular basis and potential treatments.
Researchers at the University of Gothenburg have discovered a molecule that helps more mitochondria function properly, improving energy production in cells from patients with POLG mutations. This breakthrough paves the way for a new treatment strategy and may have broader therapeutic use for other mitochondrial diseases.
A dual-principal investigator research group led by Dartmouth and the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital will test the effectiveness of video as a communication tool during patient visits for people living with Amyotrophic Lateral Sclerosis (ALS) and their caregivers.
A novel computational tool called CHOIR can accurately distinguish cells of different identities in complex biological samples, helping scientists pinpoint the discordant cells that disrupt harmony and promote disease. CHOIR overcomes limitations of existing tools by avoiding personal bias and introducing unbiased statistical frameworks.
Researchers at Temple University have discovered a new way to block the enzyme DLK, which plays a key role in neurodegenerative diseases. The breakthrough approach protects damaged neurons while preserving healthy neuron function.
Mass General Brigham researchers have identified 17 modifiable risk factors shared by stroke, dementia, and late-life depression. Modifying any one of these risk factors can reduce the risk of all three conditions, providing an opportunity to simultaneously reduce the burden of age-related brain diseases.
A new imaging technology has been developed that combines super-resolution imaging with artificial intelligence to reveal subcellular structures and dynamics in living cells. This breakthrough enables scientists to better understand the root causes of diseases, leading to improved treatments.
Researchers developed a blood test that accurately diagnoses Alzheimer's disease and measures its progression. The test correlates with the amount of tau aggregates in the brain, distinguishing between early- and late-stage diseases.
Cells dynamically adjust nuclear pore complexes like a retail store opening more checkout lines to regulate genome access. Research findings suggest that protein creation and disposal systems control the amount of NPCs in cells.
A new method has been developed for engineering specific mtDNA deletions in human cells, providing a powerful tool to model disease-associated mtDNA deletions. This approach uncovers mechanisms of histiocytosis-associated neurodegeneration and investigates how mutant stem cells co-opt regeneration to make tumors grow.
The Systems Metabolomics Centre will focus on three key areas: profiling populations of healthy people and those living with specific illnesses, leveraging state-of-the-art metabolomic technologies to drive biomarker discovery and metabolism research. The centre aims to develop non-invasive tests, detect diseases earlier and guide doct...
Scientists at the University of South Australia have developed a phospholipid complex to improve cannabidiol's effectiveness in treating epilepsy, multiple sclerosis, and other neurodegenerative diseases. The new formula increases cannabidiol's solubility by up to six times and improves its absorption in the gastrointestinal tract.
A clinical trial shows that removing amyloid plaques from the brain can delay Alzheimer's symptoms, supporting the amyloid hypothesis. The treatment reduced the risk of developing dementia in people destined to develop early-onset Alzheimer's disease.
A review article reveals CD2AP's crucial role in amyloid metabolism, tau pathology, synaptic function, and neuroinflammation in Alzheimer's disease. CD2AP deficiency accelerates plaque formation, while its loss in neurons leads to reduced spine density and impaired synaptic plasticity.
Researchers found that selfish genes use self-assembly properties to harm cells, with aggregate size and distribution being key factors in toxicity. The study also reveals an evolutionary arms race between sabotage and salvation, where rapid evolution of 'selfish' genes can lead to their own destruction.
Researchers have developed a computational tool, Spotiphy, that uses generative AI to enhance the resolution of sequencing-based spatial transcriptomics without sacrificing gene coverage. This breakthrough enables single-cell resolution in tissue imaging while maintaining full transcriptome coverage.
A new diagnostic method called flicker optoretinography (f-ORG) analyzes the retina's reaction to light, helping to detect danger before symptoms appear. The technique detects even minor changes in photoreceptors, providing valuable insights into retinal health.
Promoting cardiovascular health may help alleviate neurodegenerative disease burden in older adults, particularly among Black adults. The study found a positive correlation between cardiovascular health and biomarkers of neurodegenerative disease.
A study published in Human Gene Therapy found that over half of individuals with Niemann-Pick disease type C1 lacked neutralizing antibodies against AAV2 and AAV9. This absence of antibodies may impact the effectiveness of gene therapy treatments for this rare disorder.
Scientists repurposed the drug edaravone as an imaging probe to detect oxidative stress in brain tissue using PET scans. This technique can help diagnose neurological conditions such as ALS and Alzheimer's disease earlier, when treatment is more effective.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
Researchers develop a potential new treatment for rare genetic diseases characterized by low levels of specific proteins. By adding an artificial poly(A) tail to mRNA, they boost protein production and aim to improve symptoms in people with protein-deficient disorders.
TruDiagnostic presents its latest advancements in epigenetic testing, leveraging DNA methylation to predict disease risk. The company has developed over 1,700 Epigenetic Biomarker Proxies (EBPs), outperforming traditional biomarkers in accuracy and effectiveness.